Rgenix is a preclinical stage biotechnology company with a mission to develop first-in-class cancer drugs designed specifically to target, both primary tumors and metastasis, the main cause of mortality in cancer patients. Founded on the ground-breaking research of Dr. Sohail Tavazoie of Rockefeller University, Rgenix has developed a novel target discovery platform and is leading the revolution in next-generation cancer therapies with four separate oncology programs to treat highly aggressive cancer subtypes, including melanoma (small molecule), colorectal cancer (small molecule), and triple-negative breast cancer (small molecule and monoclonal antibodies).

News

Dr. Sohail Tavazoie and Dr. Saeed Tavazoie publish new findings on breast cancer metastasis, in Nature more

Dr. Sohail Tavazoie’s Lab publishes on a novel mechanism to combat melanoma, in Cell more

Dr. Sohail Tavazoie’s Lab publishes on a miRNA network underlying melanoma metastasis, in Cell more

In cancer, molecular signals that recruit blood vessels also trigger metastasis more